Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Trammell, Samuel A J ^a   Weidemann, Benjamin J ^a   Chadda, Ankita ^a   Yorek, Matthew S ^b   Holmes, Amey ^b   Coppey, Lawrence J ^b   Obrosov, Alexander ^b   Kardon, Randy H ^a,b   Yorek, Mark A ^a,b   Brenner, Charles ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; NICOTINAMIDE; NICOTINAMIDE-BETA-RIBOSIDE; STREPTOZOCIN;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; CORNEA; DIABETIC NEUROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INNERVATION; INSULIN RESISTANCE; LIPID DIET; LIVER; MALE; METABOLISM; MOUSE; OBESITY; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; CORNEA; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DIET, HIGH-FAT; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; NIACINAMIDE; OBESITY; PREDIABETIC STATE; STREPTOZOCIN;

EID: 84971290135     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26933     Document Type: Article

References (35)

1. Ziegler, D., et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31, 464-469, doi: 10.2337/dc07-1796 (2008).
2. Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. Diabetic neuropathy: mechanisms to management. Pharmacology & therapeutics 120, 1-34, doi: 10.1016/j.pharmthera.2008.05.005 (2008).
3. Calabek, B., Callaghan, B., & Feldman, E. L. Therapy for diabetic neuropathy: an overview. Handbook of clinical neurology 126, 317-333, doi: 10.1016/B978-0-444-53480-4.00022-9 (2014).
4. Bogan, K. L., & Brenner, C. Nicotinic Acid, Nicotinamide and Nicotinamide Riboside: A Molecular Evaluation of NAD+ Precursor Vitamins in Human Nutrition. Ann Review Nutrition 28, 115-130 (2008).
5. Bieganowski, P., & Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117, 495-502 (2004).
6. Belenky, P., et al. Nicotinamide Riboside Promotes Sir2 Silencing and Extends Lifespan via Nrk and Urh1/Pnp1/Meu1 Pathways to NAD(+). Cell 129, 473-484 (2007).
7. Trammell, S. A., Yu, L., Redpath, P., Migaud, M. E., & Brenner, C. Nicotinamide Riboside Is a Major NAD+ Precursor Vitamin in Cow Milk. J Nutr, doi: 10.3945/jn.116.230078 (2016).
8. Canto, C., et al. The NAD(+) Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity. Cell Metab 15, 838-847, doi: 10.1016/j.cmet.2012.04.022 (2012).
9. Gariani, K., et al. Eliciting the mitochondrial unfolded protein response via NAD+ repletion reverses fatty liver disease. Hepatology, n/a-n/a, doi: 10.1002/hep.28245 (2015).
10. Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-And age-induced diabetes in mice. Cell Metab 14, 528-536, doi: 10.1016/j.cmet.2011.08.014 (2011).
11. Yoon, M. J., et al. SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice. Cell metabolism 21, 706-717, doi: 10.1016/j.cmet.2015.04.002 (2015).
12. Araki, T., Sasaki, Y., & Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010-1013 (2004).
13. Sasaki, Y., Araki, T., & Milbrandt, J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 26, 8484-8491 (2006).
14. Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. Neurobiology. SARM1 activation triggers axon degeneration locally via NAD(+) destruction. Science 348, 453-457, doi: 10.1126/science.1258366 (2015).
15. Brown, K. D., et al. Activation of SIRT3 by the NAD+ precursos nicotinamide riboside protects from noise-induced hearing loss. Cell Metab 20, in press (2014).
16. Brenner, C., & Boosting N. A. D. To spare hearing. Cell Metab 20, 926-927, doi: 10.1016/j.cmet.2014.11.015 (2014).
17. Yorek, M. S., et al. Effect of diet induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in C57Bl/6J mice. J Peripher Nerv Syst, doi: 10.1111/jns.12111 (2015).
18. Yorek, M. S., et al. Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocin-induced diabetic C57Bl/6J mice. J Peripher Nerv Syst 19, 205-217, doi: 10.1111/jns.12086 (2014).
19. Hargreaves, K., Dubner, R., Brown, F., Flores, C., & Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32, 77-88 (1988).
20. Yorek, M. A. The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy. Curr Drug Targets 9, 77-84 (2008).
21. Belmonte, C., & Gallar, J. In Neurobiology of Nociceptors (eds C. Belmonte & F. Cervero) (Oxford Scholarship Online, 1996).
22. Malik, R. A., et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 46, 683-688, doi: 10.1007/s00125-003-1086-8 (2003).
23. Quattrini, C., et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 56, 2148-2154, doi: 10.2337/db07-0285 (2007).
24. Davidson, E. P., Coppey, L. J., Holmes, A., & Yorek, M. A. Changes in corneal innervation and sensitivity and acetylcholine-mediated vascular relaxation of the posterior ciliary artery in a type 2 diabetic rat. Invest Ophthalmol Vis Sci 53, 1182-1187, doi: 10.1167/iovs.11-8806 (2012).
25. Belenky, P., Bogan, K. L., & Brenner, C. NAD(+) metabolism in health and disease. Trends Biochem Sci 32, 12-19 (2007).
26. Evans, C., et al. NAD+ metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity. BMC Chem Biol 10, 2, doi: 10.1186/1472-6769-10-2 (2010).
27. Trammell, S. A., & Brenner, C. Targeted, LCMS-based Metabolomics for Quantitative Measurement of NAD Metabolites. Comput Struct Biotechnol J 4, e201301012, doi: 10.5936/csbj.201301012 (2013).
28. Agledal, L., Niere, M., & Ziegler, M. The phosphate makes a difference: cellular functions of NADP. Redox report: communications in free radical research 15, 2-10, doi: 10.1179/174329210X12650506623122 (2010).
29. Houstis, N., Rosen, E. D., & Lander, E. S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948, doi: 10.1038/nature04634 (2006).
30. Pollak, N., Niere, M., & Ziegler, M. NAD kinase levels control the NADPH concentration in human cells. J Biol Chem 282, 33562-33571, doi: 10.1074/jbc.M704442200 (2007).
31. Bieganowski, P., Seidle, H. F., Wojcik, M., & Brenner, C. Synthetic lethal and biochemical analyses of NAD and NADH kinases in Saccharomyces cerevisiae establish separation of cellular functions. J Biol Chem 281, 22439-22445 (2006).
32. Marbaix, A. Y., et al. Occurrence and subcellular distribution of the NADPHX repair system in mammals. Biochem J 460, 49-58, doi: 10.1042/BJ20131482 (2014).
33. Richter, C. NADP+ phosphatase: a novel mitochondrial enzyme. Biochemical and biophysical research communications 146, 253-257 (1987).
34. Berthelier, V., Tixier, J. M., Muller-Steffner, H., Schuber, F., & Deterre, P. Human CD38 is an authentic NAD(P)+ glycohydrolase. Biochem J 330 (Pt 3), 1383-1390 (1998).
35. Rutter, J., Reick, M., Wu, L. C., & McKnight, S. L. Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293, 510-514, doi: 10.1126/science.1060698 (2001).